Crystalline form of vascular leakage blocker compound
US12103945B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 5, 2020 |
| Grant date | Oct 1, 2024 |
| Priority date | — |
| Expiry date | Jul 16, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a crystalline form of (E)-methyl 6-((3S,8S,9S,10R,13S,14S,17R)-3-(((5S,6R)-5-acetoxy-6-(acetoxytnethyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-10,13-dimethyl-2,3,4,7,8,9,10.11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)hept-5-enoate and a blood vessel leak blocker comprising the same. The novel crystalline form has high purity, excellent stability, excellent long-term storage and pharmaceutical stability, and can be used as a vascular leakage blocker, so it is very advantageous in producing high-quality drug substances.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.